Posted by Michael Wonder on 14 Jul 2020
Verrica Pharmaceuticals receives complete response letter from the FDA for its new drug application for VP-102 for the treatment of molluscum contagiosum
14 July 2020 - Complete response letter requests additional chemistry, manufacturing, and controls and human factors information.
Verrica Pharmaceuticals today announced that the U.S. FDA has issued a complete response letter regarding the new drug application for VP-102, the Company’s investigational, proprietary, drug-device combination for the treatment of molluscum contagiosum (molluscum).
The Company had previously disclosed receipt of a letter from the FDA in which the agency noted deficiencies that precluded discussion of labelling and post-marketing requirements/commitments.
